secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001171843-25-005124
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose TUSCANY trial advances to 160 mg TUS dose; receives additional $1.1M loan from Hanmi
--------------------------------------------------------------------------------

- CSRC approved escalation to 160 mg TUS dose after no dose-limiting toxicities at 40, 80, and 120 mg cohorts.
- TUS+VEN+AZA triplet achieved CRs and MRD negativity in patients with adverse TP53 and FLT3-ITD mutations.
- Aptose received $1.1M advance from Hanmi under $8.5M loan, bringing total advances to $5.6M.
- Enrollment open for 160 mg cohort; all 120 mg patients remain on study.
- Trial anticipates enrolling 18-24 patients by late 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005124/0001171843-25-005124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005124/f8k_080625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer